Zobrazeno 1 - 10
of 1 099
pro vyhledávání: '"William D, Figg"'
Autor:
Giorgia Fiorini, Stephen A. Marshall, William D. Figg, William K. Myers, Lennart Brewitz, Christopher J. Schofield
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Hypoxia inducible transcription factors (HIFs) mediate the hypoxic response in metazoans. When sufficient O2 is present, Fe(II)/2-oxoglutarate (2OG)-dependent oxygenases (human PHD1-3) promote HIFα degradation via prolyl-hydroxylation. We r
Externí odkaz:
https://doaj.org/article/38038eab48c0475db465b4d887b902a3
Autor:
Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody, Dhwani Patel, Urvi A. Shah, Carlyn Rose Tan, David J. Chung, Oscar B. Lahoud, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Matthew J. Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemirovsky, Andriy Derkach, Oluwatobi Arisa, Cody J. Peer, William D. Figg, Saad Z. Usmani, Ola Landgren, Alexander M. Lesokhin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/fe04ce63af1445c2a54d5c8efb6e5ac9
Autor:
Unsun Lee, Ludmila Szabova, Victor J. Collins, Melanie Gordon, Kristine Johnson, Deborah Householder, Stephanie Jorgensen, Lucy Lu, Laura Bassel, Fathi Elloumi, Cody J. Peer, Ariana E. Nelson, Sophia Varriano, Sudhir Varma, Ryan D. Roberts, Zoe Weaver Ohler, William D. Figg, Shyam K. Sharan, Yves Pommier, Christine M. Heske
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
IntroductionThe topoisomerase 1 (TOP1) inhibitor irinotecan is a standard-of-care agent for relapsed Ewing sarcoma (EWS), but its efficacy is limited by chemical instability, rapid clearance and reversibility, and dose-limiting toxicities, such as di
Externí odkaz:
https://doaj.org/article/10caaca1b67e432ab0d7e84fc26b685f
Autor:
Nebojsa Skorupan, Cody J. Peer, Xianyu Zhang, Hyoyoung Choo-Wosoba, Mehwish I. Ahmad, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Yunkai Yu, Guillaume Joe Pegna, Seth M. Steinberg, Shelley S. Kalsi, Liang Cao, William D. Figg, Jane B. Trepel, Ira Pastan, David FitzGerald, Christine Alewine
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundLMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin (iTox) carrying a Pseudomonas exotoxin A payload that has shown promise against solid tumors, however, efficacy is limited by the development of neutralizing anti-drug antibod
Externí odkaz:
https://doaj.org/article/7b50e02d4e8d4d54b44bd8cfb4b2d620
Autor:
Blaire E. Barton, Matthew K. Collins, Cindy H. Chau, Hyoyoung Choo-Wosoba, David J. Venzon, Christian Steinebach, Kathleen M. Garchitorena, Bhruga Shah, Eric L. Sarin, Michael Gütschow, William D. Figg
Publikováno v:
Biomolecules, Vol 14, Iss 6, p 725 (2024)
Immunomodulatory imide drugs (IMiDs) play a crucial role in the treatment landscape across various stages of multiple myeloma. Despite their evident efficacy, some patients may exhibit primary resistance to IMiD therapy, and acquired resistance commo
Externí odkaz:
https://doaj.org/article/d74ba37251e44718a94b951da86fbe1b
Autor:
Cecilia Monge, Changqing Xie, Yuta Myojin, Kelley L. Coffman‐D'Annibale, Donna Hrones, Gagandeep Brar, Sophie Wang, Anuradha Budhu, William D. Figg, Maggie Cam, Richard Finney, Elliot B. Levy, David E. Kleiner, Seth M. Steinberg, Xin Wei Wang, Bernadette Redd, Bradford J. Wood, Tim F. Greten
Publikováno v:
Cancer Medicine, Vol 13, Iss 3, Pp n/a-n/a (2024)
Abstract Background Current standard of care for advanced biliary tract cancer (BTC) is gemcitabine, cisplatin plus anti‐PD1/PD‐L1, but response rates are modest. The purpose of this study was to explore the efficacy and safety of durvalumab (ant
Externí odkaz:
https://doaj.org/article/ace3cc3c93a540859188850b14cf317a
Autor:
Sharyn D. Baker, William D. Figg
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 1, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/420aec1fe77147a09b1a673873dbbab7
Autor:
Christopher B. Cole, Maria Pia Morelli, Massimo Fantini, Markku Miettinen, Patricia Fetsch, Cody Peer, William D. Figg, Tyler Yin, Nicole Houston, Ann McCoy, Stanley Lipkowitz, Alexandra Zimmer, Jung-min Lee, Miroslava Pavelova, Erin N. Villanueva, Kathryn Trewhitt, B. Brooke Solarz, Maria Fergusson, Sharon A. Mavroukakis, Anjum Zaki, Kwong Y. Tsang, Philip M. Arlen, Christina M. Annunziata
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-17 (2023)
Abstract Background NEO201 is a humanized IgG1 monoclonal antibody (mAb) generated against tumor-associated antigens from patients with colorectal cancer. NEO-201 binds to core 1 or extended core 1 O-glycans expressed by its target cells. Here, we pr
Externí odkaz:
https://doaj.org/article/156401e08d7b44f9b984a38a26842574
Autor:
Guillaume Joe Pegna, Min‐Jung Lee, Cody J. Peer, Mehwish I. Ahmad, David J. Venzon, Yunkai Yu, Akira Yuno, Seth M. Steinberg, Liang Cao, William D. Figg, Renee N. Donahue, Raffit Hassan, Ira Pastan, Jane B. Trepel, Christine Alewine
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4236-4249 (2023)
Abstract LMB‐100 is a novel immune‐conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB‐100 ± nab‐paclitaxel. Participant blo
Externí odkaz:
https://doaj.org/article/b0426dc9f76e4ee5ac65fe73a10166c9
Publikováno v:
Cancer Biology & Therapy, Vol 23, Iss 1, Pp 186-190 (2022)
In the last decade, many life-prolonging therapeutic options have emerged for metastatic castration-resistant prostate cancer (mCRPC). The recent VISION trial is the first to demonstrate a survival benefit of Lutetium-177[177Lu]Lu-PSMA-617 in post-ch
Externí odkaz:
https://doaj.org/article/bb7e2ec6e1ff4a27993d449ea060b88c